Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CMA1 | P23946 | 13/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409429 | 0.86 | KLK5 (0.40) | KMT2A | |
| SCHEMBL4412440 | 0.83 | CMA1 (0.46) | KMT2ACMA1ELANECCR1 | |
| SCHEMBL4405352 | 0.82 | MEN1 (0.40) | KMT2ACMA1ELANEMEN1BACE1 | |
| SCHEMBL4406392 | 0.81 | CMA1 (0.43) | KMT2ACMA1ELANEMEN1BACE1 | |
| SCHEMBL4412431 | 0.80 | L3MBTL1 (0.46) | KMT2AMEN1 | |
| SCHEMBL2841930 | 0.73 | HPGD (0.46) | KMT2AMEN1 | |
| SCHEMBL2841931 | 0.73 | HPGD (0.46) | KMT2AMEN1 | |
| SCHEMBL4409465 | 0.72 | CMA1 (0.49) | KMT2ACMA1ELANEMEN1 | |
| SCHEMBL8060765 | 0.72 | HDAC3 (0.46) | — | |
| SCHEMBL4406391 | 0.71 | KLK5 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608577-B2 | Peptidyl ketones as inhibitors of DPIV | OSI PHARMACEUTICALS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| EP-1434792-A2 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | Probiodrug AG (DE) | 2004-07-07 | — | — | EP | disclosed |
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | PROSIDION LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
| WO-2003033524-A2 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | PROBIODRUG AG (DE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | GLS, SLC5A1, BCKDK | KMT2A 4302/4885CMA1 889/4885ELANE 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.